darunavir + ritonavir + etravirine

Darunavir + ritonavir + etravirine is a potent antiretroviral combination therapy used for treating HIV-1 infection, particularly in treatment-experienced patients with multidrug resistance. This regimen combines: - **Darunavir**: A second-generation HIV protease inhibitor designed to combat resistance to standard HIV therapy - **Ritonavir**: A pharmacokinetic enhancer (boosting agent) that inhibits CYP3A4, thereby increasing darunavir plasma concentrations - **Etravirine**: A non-nucleoside reverse transcriptase inhibitor (NNRTI) effective against HIV strains resistant to other NNRTIs Studies have shown this combination to be highly effective, with one French study demonstrating viral suppression in 86% of heavily treatment-experienced patients after 48 weeks[5]. The combination has also shown impressive results in adolescents with extensive prior treatment experience[1].